R&D Trends

Cancer Research Technology Pioneer fund, BACIT, Sareum ink agreement

Friday, September 27, 2013 11:18 AM

The Cancer Research Technology Pioneer Fund (CPF), Battle Against Cancer Investment Fund (BACIT) and drug discovery company Sareum, have entered into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.

More... »

CANbridge, Azaya enter agreement

Friday, September 27, 2013 11:10 AM

CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has partnered with Azaya Therapeutics in San Antonio, Texas, to develop and commercialize Azaya’s investigational drug, ATI-1123, for treatment of non-small cell lung cancer (NSCLC), and potentially other solid tumor cancer indications, in China, Taiwan and South Korea.

More... »

Global Health Investment Fund launched for late-stage vaccines

Friday, September 27, 2013 10:59 AM

A new investment fund structured by JPMorgan Chase and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

More... »

Allergan, Medytox enter licensing agreement

Friday, September 27, 2013 10:49 AM

Allergan, a multi-specialty healthcare company, and Medytox, a research-based biopharmaceutical company, have entered into a license agreement. Allergan will pay Medytox an upfront payment of $65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize neurotoxin product candidates currently in development, including a potential liquid-injectable product.

More... »

Ipsen to relocate R&D activities to Cambridge, Mass.

Friday, September 27, 2013 10:28 AM

Ipsen plans to relocate its U.S. R&D operations to Cambridge, Mass., in 2014. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospital centers, medical schools, biotech companies and universities, thereby further promoting and facilitating partnerships and open innovation.

More... »

Amgen, ShanghaiTech University plans for Amgen China R&D center

Wednesday, September 25, 2013 03:12 PM

Amgen and ShanghaiTech University have partnered for the advancement of biopharmaceutical discovery and translational research in China, with plans for Amgen to open a China R&D center at ShanghaiTech University.

More... »

Chrysalis BioTherapeutics receives $1.5m from the National Cancer Institute

Wednesday, September 25, 2013 12:33 PM

Chrysalis BioTherapeutics has announced receipt of a $1.5 million contract from the National Cancer Institute (NCI) to continue its development of Chrysalin to mitigate radiotherapy-induced damage to normal brain tissue.

More... »

AbbVie, Galapagos to co-develop cystic fibrosis therapies

Wednesday, September 25, 2013 12:24 PM

Galapagos and AbbVie have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.

More... »

Janssen, PATH collaborate for Rilpivirine

Wednesday, September 25, 2013 12:21 PM

Janssen R&D Ireland has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) against HIV infection.

More... »

H3 Biomedicine, Selvita collaborate

Monday, September 23, 2013 01:39 PM

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical company specializing in  discovering and developing precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and feasibility of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »